Sponsored Links
| US FDA Advisory Committee Makes Recommendation On New Drug Application For Vandetanib In Advanced Medullary Thyroid Cancer |
 |
 |
 |
| Medical News - Ear, Nose and Throat | |||
|
AstraZeneca (NYSE: AZN) announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC)... Read more: Ear, Nose and Throat News From Medical News Today
|